Read in and find out

View publications of the SATURN3 consortium or individual members. Once new publications are available, we list them here. Open access listings are linked directly to the full text version. All others lead to the respective journal repository or publisher. For SATURN3 press releases, please go to News.

List of SATURN3 Publications (selected):

2025

Articles:

15

Cheytan T, Schneider M, Wurth R, et al. Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropism (PMID: 40057730). Mol Cancer. 2025.
Denk D, Ramakrishnan M, Conche C, et al. IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis (PMID: 40023157). Immunity. 2025.
Denkert C, Rachakonda S, Karn T, et al. Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping (PenelopeB) (PMID: 39933898). Cancer Cell. 2025.
Ghadimi M, Pelzer U, Besselink MG, et al. Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial (PMID: 39915735). BMC Cancer. 2025.
Hofer S, Frasch L, Brajkovic S, et al. Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response (PMID: 39838187). Mol Syst Biol. 2025.
Keyl J, Keyl P, Montavon G, et al. Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence (PMID: 39885364). Nat Cancer. 2025.
Metzenmacher M, Zaun G, Trajkovic-Arsic M, et al. Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA (PMID: 39478658). Mol Oncol. 2025.
Rodel F, Fleischmann M, Diefenhardt M, Dapper H, Hoffmann A, Rödel C, Martin D, Fokas E. Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer. Nat Rev Clin Oncol 2025 accepted.
Schwerd-Kleine P, Wurth R, Cheytan T, et al. Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility (PMID: 40022208). Int J Cancer. 2025.
Starostecka M, Jeong H, Hasenfeld P, et al. Structural variant and nucleosome occupancy dynamics postchemotherapy in a HER2+ breast cancer organoid model (PMID: 39993200). Proc Natl Acad Sci U S A. 2025.
Tapia Contreras C, Falke JD, Seifert DM, et al. KRAS(G) (12C)-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening (PMID: 39253995). Mol Oncol. 2025.
Thiel V, Renders S, Panten J, et al. Characterization of single neurons reprogrammed by pancreatic cancer (PMID: 39961335). Nature. 2025.
Thiel V., Panten J., Dross N., Bauer K., Azorin D., Henriques V., Vogel V., Klein C., Leppä AM., Barriuso Ortega I., Schwickert J., Ourailidis I., Mochayedi J., Mallm JP., Müller-Tidow C., Monyer H., Neoptolemos J., Hackert T., Stegle O., Odom DT, Offringa R., Stenzinger A., Winkler F., Sprick M., Trumpp A. Retrograde tracing and molecular analysis of single neurons invading pancreatic cancer reveal actionable dependencies. Nature (accepted).
Wurth R, Donato E, Michel LL, et al. Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling (PMID: 39753722). Nat Cancer. 2025.
Zhao B, Fang R, Schurmann H, et al. PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma (PMID: 40188436). Cell Rep. 2025.

2024

Articles:

13

2023

Articles:

11

2022

Articles:

3

RESOURCES